Prolia
Amgen’s Prolia achieves positive top-line Phase III results after 12 months
August 30, 2016Manufacturing and Production, Research and Development Amgen, Prolia, denosumab, phase III
Amgen has announced that its drug Prolia (denosumab) generated positive Phase III results investigating its safety and efficacy in patients …
Amgen’s denosumab may help check breast cancer in women with BRCA1 gene – Study
June 21, 2016Manufacturing and Production, Research and Development Amgen, Prolia, Xgeva, biotech, breast cancer, drug trial, genetics
US biotech firm Amgen’s (Nasdaq: AMGN) Prolia (denosumab) to treat osteoporosis and Xgeva to prevent fractures in cancer patients, may …
Amgen files high earnings for Q1
April 22, 2015Sales and Marketing AMG 334, Amgen, Corlanor, Kyprolis, Prolia, Q1, Xgeva, brodalumab, myeloma, osteoporosis
Amgen has boosted its first quarter profit by 51% due to surging drug sales and ongoing cuts that paved the …
Amgen to wield axe on 2,900 jobs
July 30, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, Prolia, job cuts
Amgen has announced this morning that it will make swingeing cuts in the US over the next two years as …
Amgen bone cancer drug Xgeva approved in Europe
July 18, 2011Sales and Marketing Amgen, Prolia, Xgeva, denosumab
Amgen’s bone cancer drug Xgeva (denosumab) has been approved in Europe to prevent serious bone problems in cancer patients. Already …
Denosumab approved for bone cancer use
November 19, 2010Sales and Marketing Amgen, Cancer, Prolia, Xgeva, denosumab
Amgen’s denosumab has been approved in the US to prevent serious bone problems in patients with solid tumour cancers. Denosumab …
NICE halts Prolia appraisal
August 2, 2010Sales and Marketing Amgen, NICE, Prolia
NICE says it has been forced to terminate a review of Amgen’s bone density drug Prolia after the US biotech …
Prolia gets early thumbs up from NICE
June 18, 2010Sales and Marketing Amgen, NICE, Prolia
Amgen’s new treatment to prevent bone fractures caused by osteoporosis has been given preliminary approval from the UK’s cost effectiveness …
Amgen’s Prolia approved in Europe
June 1, 2010Sales and Marketing Amgen, Prolia
A blockbuster future is predicted for the osteoporosis treatment Prolia, with global sales predicted to reach $5 billion.European regulators have …
Latest content
Ofichem acquires US drug substance CDMO Kinentia
Jager-van Dijk is new Arletta Pharma Solutions CEOÂ
Tridem begins phase Ib trial of Parkinson’s disease vaccine
